Ryan Specialty Holdings

RYAN · NYSE

$42.89+$2.12 (+5.20%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $40.77

RYAN analyst rating

HoldConsensus of 17 analysts over the last 12 months. 47% rate it a buy.

Strong buy0
Buy8
Hold7
Underperform2
Sell0

12-month price target · 20 analysts

Average $52.28 (+21.9% upside)

Low: $41.41
Now: $42.89
High: $79.80

Upgrades and downgrades

The latest rating actions, newest first

RYAN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 12, 2026	Maintains	Equal-Weight	$43.00 → $41.00	60%
Mizuho	Oct 7, 2026	Maintains	Neutral	$43.00 → $40.00	58%
Piper Sandler	Oct 6, 2026	Maintains	Neutral	$48.00 → $40.00	73%
Mizuho	Sep 16, 2026	Maintains	Neutral	$48.00 → $43.00	58%
Morgan Stanley	Aug 19, 2026	Maintains	Overweight	$48.00 → $50.00	49%
UBS	Aug 3, 2026	Maintains	Buy	$50.00 → $55.00	68%
Citigroup	Aug 3, 2026	Maintains	Buy	$50.00 → $53.50	59%
JP Morgan	Aug 3, 2026	Maintains	Underweight	$39.00 → $45.00	81%
Wells Fargo	Aug 3, 2026	Maintains	Equal-Weight	$39.00 → $43.00	60%
Cantor Fitzgerald	Aug 3, 2026	Maintains	Neutral	$34.00 → $41.00	62%

The case for and against

Updated Aug 4, 2026

Bull case

Ryan Specialty Holdings is experiencing strong organic revenue growth, but this is overshadowed by competition and declining rates in the market. The company has lowered its guidance for 2026 due to these factors, and margins are expected to be compressed due to various reasons such as top-line pressure and higher healthcare costs. While the company has announced a one-time option grant program and is encouraged by the momentum of data center activity, they are anticipating more moderate growth in the coming year. Overall, the company's revenue and adjusted EBITDAC margins were lower than expected, but they still reported solid overall organic growth.

Bear case

Ryan Specialty Holdings is facing multiple headwinds such as lower than expected margins, a decline in organic growth due to intense competition in the property insurance market, and a reduction in wholesale brokerage commissions and fees. Additionally, their guidance for 2026 suggests a slowdown in organic growth and limited margin expansion. The lower than expected revenue and EPS reported for the fourth quarter also raise concerns about the company's performance. Furthermore, their decision to prioritize share buybacks over M&A and organic growth investments in their capital allocation strategy raises questions about their future growth potential.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.